EcoOnline Celebrates Longstanding Partnership with Menzies Aviation, Driving Safety Culture Across the Globe
EcoOnline is proud to celebrate the continued success of its partnership with Menzies Aviation, the leading service partner to the world’s airports and airlines. Since 2019, EcoOnline has played a key role in enhancing the company’s MORSE (Menzies Operating Responsibly, Safely and Efficiently) system, driving safety culture and compliance across the company’s global network.
With a presence at more than 295 airports in over 65 countries, Menzies Aviation operates in high-risk environments, where safety is embedded in its DNA. As Malcolm Rae, Head of Risk Systems & Data at Menzies, reflects, “We influence safety from the moment passengers walk into an airport to when they leave. We live and breathe it day in, day out—not just in the risk and safety team, but every employee takes it extremely seriously.”
Technology That Drives Safety at Every Level
The longstanding collaboration with EcoOnline has enabled Menzies Aviation to implement a more efficient, data-driven approach to incident reporting, risk management and compliance tracking. Using EcoOnline’s advanced EHS (environment, health, and safety) solution—the technology behind Menzies’ MORSE reporting system—employees are empowered to quickly identify risks, make informed decisions, and proactively address safety risks in real time.
Since adopting EcoOnline’s platform in 2019, Menzies has seen remarkable improvements:
- 128% increase in employee hazard reporting.
- Serious personal injury reduced from 1.8 per 1,000 full-time employees in 2019 to 0.94 in 2022 and 0.7 in 2023.
"If you want to be an industry leader, you've got to know where your risks are, and that starts with empowering every employee to act. EcoOnline’s EHS platform equips everyone with the tools to report hazards and ensure our people go home safely," said Graham Cowing, Vice President of Safety Standards, Menzies Aviation.
Board Commitment to Safety
Safety at Menzies is championed at every level, from frontline workers to the boardroom. Graham commented:"Safety is a core value that starts with leadership. Every executive member is committed to getting involved, and initiatives like ‘Take 10 for Safety,’ where every board meeting begins with a safety-focused discussion, are supported by real-time dashboards from EcoOnline. These insights keep safety central to decision-making and drive accountability across the organisation."
MORSE: A system, culture and celebration
Menzies’ approach to safety is defined by its MORSE cultural mindset, MORSE safety systems, and immersive bi-annual MORSE Week events. Its most recent MORSE Week, which took place from 28 October – 1 November 2024 focused on emergency response planning, offering tools, support, and guidance to help its global teams reaffirm their commitment to safety through learning and team-building opportunities.
Tom Goodmanson, CEO of EcoOnline, commented, "By prioritising safety and collaboration, Menzies Aviation—together with EcoOnline—is setting new benchmarks for industry standards, ensuring a safer, more secure environment for employees and customers. It’s impressive that Graham still says, ‘more work is to be done,’ as it reflects Menzies’ commitment to continuous improvement."
Learn from Menzies’ safety success—explore the full case study here.
Visit ecoonline.com to immediately and positively impact your workplace safety and sustainability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116891021/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom